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There is ongoing debate regarding the optimal surgical treatment of complex proximal humeral fractures in 
elderly patients. Using a cost-utility analysis, the aim of this study was to evaluate the cost-effectiveness of 
reverse total shoulder arthroplasty (RTSA) compared to hemiarthroplasty (HA) in the management of these 
fractures. 
Methods 
Decision trees and Markov modelling were derived based on data from the published literature. A single-
payer perspective with a willingness to pay threshold of CAD $50,000 and a lifetime time horizon was used. 
The incremental cost-effectiveness ratio (ICER) was used as the study’s primary outcome measure. 
Results 
In comparison to HA, the incremental cost per QALY gained for RTSA was $13,679. One-way sensitivity 
analysis revealed the model to be sensitive to the RTSA implant cost and the RTSA procedural costs. The 
ICER of $13,679 is well below the WTP threshold of $50,000 and probabilistic sensitivity analysis 
demonstrated that 92.6% of model simulations favored RTSA.    
Conclusions 
Our economic analysis found that RTSA for the treatment of complex proximal humeral fractures in the 
elderly is the preferred economic strategy when compared to HA. The ICER of RTSA is well-below standard 
willingness to pay thresholds, and its estimate of cost-effectiveness is similar to other highly successful 




Fractures of the proximal humerus are common debilitating fractures in the elderly. Due to the impaired bone 
quality and frailty in this patient population there is an increased incidence of complex and unstable proximal 
humeral fractures [1, 2].  Although the benefits of surgical interventions remain controversial [3], locked 
plate fixation has become a standard surgical treatment for many fracture patterns [4-6]. Despite the 
preference for internal fixation [7], fractures with complex patterns and calcar comminution can be difficult 
to successfully treat with plate fixation [6, 8-11]; as a result, arthroplasty has increasingly been used to 
manage these complex fractures in elderly patients who have low functional demands [12-17]. 
 
Successful hemiarthroplasty (HA) can be challenging as anatomic healing of the tuberosities is essential in 
order to improve the postoperative functional outcome [16]. Reverse total shoulder arthroplasty (RTSA), in 
contrast, has gained recent popularity because its success can be independent of tuberosity malposition or 
rotator cuff integrity. Although this represents a substantial design advantage, widespread adoption of RTSA 
has been tempered by high implant costs and sparse salvage options for failure [17]. There is ongoing debate 
in orthopaedic surgical community on whether RTSA or HA is the preferable management strategy of 
complex displaced proximal humeral fractures in elderly patients.  
 
Recently, several clinical trials and systematic reviews [18-27] have compared both interventions with regard 
to their functional outcomes and their associated risks for complications.  Briefly, these studies have 
suggested improved functional outcomes with a higher rate of complications in the RTSA groups.   The 
results of these studies enhance our understanding of the clinical effectiveness of these treatments; however, 
they do not inform the economic value of each strategy. With constrained health budgets, consideration of the 
cost-effectiveness of management strategies is becoming increasingly more important for both surgeons and 
policy makers.  Therefore, the aim of the current study is to evaluate the cost-effectiveness of RTSA 
compared with HA in the treatment of complex proximal humeral fractures in elderly patients. The following 
economic evaluation is based on the assumption that the treating surgeon has opted for surgical treatment, in 
particular, joint arthroplasty due to the complexity of the fracture. Therefore, a non-operative comparison 
was not included in the model and the included fracture pattern is deemed inappropriate for treatment using 





Based on data from published literature, we conducted a cost–utility analysis using decision tree and Markov 
modelling. A single-payer Canadian provincial government perspective (Ontario Ministry of Health) and a 
lifetime time horizon were used. The incremental cost-effectiveness ratio (ICER) was the primary metric of 
cost-effectiveness.  We conducted multiple sensitivity analyses to explore the robustness of our findings. To 
determine which of the treatments would be the economically preferred intervention, we used a willingness-
to-pay (WTP) threshold of $50,000 per incremental QALY gained [28].   
 
Model Overview 
TreeAge Pro 2011 (TreeAge Software, Inc, Williamstown, MA) was used to construct a decision tree for the 
first two years of the model (Figure 1) followed by a Markov model for the remainder of the lifetime.  At the 
end of each node of the decision tree, a Markov process starts which extends the time horizon in the decision 
tree for the remainder of a patient’s lifespan (Figure 2). Briefly, all individuals enter the Markov model with 
their health state from the end of the 2-year horizon and then undergo one-year cycles in the Markov model. 
With every one-year cycle, individuals either maintain their current health state or transition to a different 
state.   
 
Base Case Scenario 
The base case scenario provides the clinical context for the economic analysis. The analysis was performed 
based on a 72-year-old female patient with a complex proximal humerus fracture and general health suitable 
for either arthroplasty procedure (American Society of Anaesthesiologists Physical Status Classification 1 or 
2). The base case demographics were chosen to represent the most commonly encountered clinical scenario 
based on age and gender [20, 21].  
 
Literature Search 
We conducted a comprehensive search of the published literature to identify: 1) systematic reviews that 
compare RSTA versus HA and report complication rates and functional outcomes, and 2) clinical studies that 
evaluate the clinical efficacy of RTSA and HA for the treatment for complex proximal humeral fractures in 
elderly patients.  Our literature search identified four systematic reviews [18-21] and 21 clinical studies 
including 13 single intervention case series [12-17, 29-35], five retrospective comparative studies [24-27, 
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36], one prospective cohort study [23], and one randomized controlled trial [22].  The studies identified from 
our literature search informed the complication rates and the assignment of the health states within the model. 
 
Complication Rates 
Complication rates were then derived from the studies identified in our literature search (Table 1).  
Complications were differentiated as either not requiring revision surgery (e.g. neuropraxia, cellulitis treated 
with antibiotics, dislocation amenable for closed reduction, etc.) or requiring revision surgery (e.g. deep 
infection, recurrent dislocation, implant loosening, etc.). Revision surgery was then classified as either minor 
surgery (e.g. wound excision, irrigation with change of the mobile components, etc.) or major surgery (e.g. 
implant revision with change of stem, glenoid component, etc.).  The early complication rate for RTSA was 
15% [18-21], with 40% of these early complications cases requiring revision surgery [18-21].  For HA, the 
early complication rate was 10% [12, 18-21], with 50% of cases requiring revision surgery [12, 18-21]. If an 
early complication required surgical intervention, the probability of a major revision was estimated to be 50% 
in both treatment groups [12, 18-21].    
 
For the late complications within the Markov modelling, estimates for the annual complication rates were 
based on values reported in large meta-analyses [12, 18, 19, 37]. As the Markov model begins two years after 
implantation of the prosthesis and the studies included into the meta-analyses had a mean follow up of about 
3 to 4 years, the estimates were modified in order to account for a longer interval (i.e. the mean patient’s 
survival). The annual probability of a late infection was assumed to be 0.2% [12, 18, 19, 37] and aseptic 
loosening was 0.5% [12, 18, 19]. The probability of sustaining a periprosthetic fracture was estimated at 
0.1% per year [12, 18, 19]. We also assumed that patients with a late complication would spend one-year in 
an impaired health state before they return to either their previous health state (post-periprosthetic fracture or 
aseptic loosening) or to a health state of “poor function/no pain” after late infection.   
 
Health States 
All patient outcomes were defined by five health states: “excellent function”, “good function”, “poor 
function/no pain”, “poor function/pain”, and “death”.  We estimated that the majority of patients who 
required major revision surgery would have poor functional outcomes [22]. For the remainder of patients, the 
health states were defined by a patient’s forward shoulder flexion and pain. Beta distributions were used to 
estimate the proportion of individuals with elevation <90°, 90° to 120°, and >120° without chronic pain; as 
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well as the distribution of individuals with chronic pain scores greater than 5/10 [38].  If a patient had pain 
>5/10, it was assumed the patient also had poor function; conversely, it was assumed that no patients would 
have pain >5/10 and still be described as good or excellent function. The description of each health state and 
its probability within the decision tree are listed in Table 2.  
 
Patients with a health state of “excellent function”, “good function” or “poor function/no pain” who have a 
late complication were modelled to transition to a health state of “poor function/pain”. Individuals with a 
health state of “poor function/pain” who have a complication transition to a sixth temporary health state 
(“very poor function/pain”) added for modelling this specific scenario. As general health is expected to 
deteriorate over time, 2% of the individuals in each health state group were modelled to transition to an 
inferior state per year. The probability of death at any point in the model was estimated based on Canadian 
Census life tables and represents age-specific all-cause mortality risk [39].  
 
Utility Values 
Utility values were derived from patient outcomes in several high-quality studies [12, 31], and cross-
referenced with EQ-5D values reported in a third study that reported 2-year outcomes on one the two 
interventions [12]. The authors used clinical experience to confirm the face validity of the estimates. 
Clinically plausible ranges for each outcome were included with model variation in the patient population at 
each health state. The utility values for each of the health states within the model are listed in Table 1. 
QALYs were then calculated based on the duration of time spent in a particular health state multiplied by the 
utility value of the given health state. 
 
Estimation of Costs 
All costs are reported in 2014 Canadian dollars (CAD), and both costs and health state values were 
discounted 5% annually, following Canadian guidelines [41]. Hospital costs were estimated using data from a 
provincial government initiative that collects standardized case costing data from nearly 50 hospitals in 
Ontario, Canada (Ontario Case Costing Initiative) [42]. Billing costs for physician services were estimated 
using the Ontario Schedule of Benefits [43].  Implant costs were estimated based on regional pricing.  To 
model conversions from HA to RTSA, we assumed that half of the early major revisions of HA would be 
conversions to RTSA; accordingly, the estimated implant cost for major revisions of HA were set to be the 
median cost of an HA and RTSA implants. Similarly, we assumed that late deep infections of HA were 
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accompanied by a loss of rotator cuff function and would be treated with an RTSA implant.  All model cost 
estimates are listed in Table 1. 
 
Calculation of the Incremental Cost-Effectiveness Ratio (ICER) 
The ICER was calculated as the difference in costs between the two treatments (RTSA and HA) divided by 
the difference in quality-adjusted life years (QALYs) between the two treatments (RTSA and HA).  
 
Sensitivity Analysis 
In order to explore potential uncertainties in model variables, we conducted a one-way sensitivity analysis on 
the RTSA implant costs and a two-way sensitivity analysis on the RTSA implant costs and the RTSA early 
complication rate [44].  As the use of RTSA in the treatment of proximal humerus fractures has not been 
fully established, it is anticipated that the implant costs will decrease with time and that early complications 
will become less frequent with increasing surgical experience with this technique.  We chose a RTSA 
implant cost range from $1,000 to $10,000 for the sensitivity analysis. The base case RTSA procedural costs 
excluding the implant were estimated to be $21,059 (Table 1).  We chose a range from $8,000 to $40,000 for 
the sensitivity analysis. With regard to the early complications, a rate of 15% was modelled for the RTSA 
treatment arm based on the literature [18-21], and a range from 0% to 35% was used for sensitivity analysis.  
 
To account for inherent uncertainty in all variable estimates and to further evaluate the robustness of the 
model, a probabilistic sensitivity analysis (PSA) was performed using a Monte Carlo simulation of 100,000 
runs. In PSA, all model parameters are assigned a probability distribution, and in each run of the model, a 
random sample from those distributions is drawn. Beta distributions were used for probabilities and gamma 





Incremental QALYs, Costs, and Cost Effectiveness  
Based on our lifetime model, the treatment of a proximal humerus fracture in an elderly population with HA 
was associated with a cost of $18,348 and 5.76 QALYs gained. Treatment of this fracture with RTSA 
resulted in a cost of $24,219 and 6.19 QALYs gained (Table 3).  While RTSA was associated with $5,871 
more cost than HA, it also provided 0.43 more QALYs over the patient’s lifetime when applied to the base 
case scenario.  Therefore, the incremental cost per QALY gained for RTSA was $13,679.  
 
Sensitivity Analyses 
One-way sensitivity analysis revealed the model to be sensitive to the RTSA implant cost and the RTSA 
procedural costs. RTSA treatment becomes the more cost-effective treatment, compared to HA, within two 
years of the initial procedure if the implant cost is less than $5,674 or the overall procedural costs for RTSA 
remain less than $12,733. When costs are held constant in the model the model, the RTSA early complication 
rate would have to exceed 38% before HA provided more QALYs. Two-way sensitivity analysis suggested 
RTSA to be cost-effective compared to HA within the first two years of surgery with an early complication 
rate as high as 25% (if RTSA implant cost was approximately $3,000); or conversely, RTSA implant cost 
could be as high as $8,500 if its early complication rates were 5% (Figure 3).   
 
Probabilistic sensitivity analysis demonstrated that 92.6% of model simulations favored RTSA at the $50,000 
WTP threshold (Figure 4). The cost-effectiveness acceptability curve also demonstrates that RTSA is 




The aim of this economic study was to determine the cost-effectiveness of reverse total shoulder arthroplasty 
(RTSA) compared with hemiarthroplasty (HA) in the treatment of complex elderly proximal humeral 
fractures. A cost–utility analysis from a single-payer perspective was performed using data from the current 
literature and decision tree and Markov modelling techniques. The results of this analysis suggest that RTSA 
is more expensive but also more effective; with an ICER of $13,679 per incremental QALY gained. 
Therefore, RTSA is likely to be cost-effective compared to HA. 
 
To the authors’ knowledge, this is the first study comparing cost-effectiveness of RTSA versus HA in 
fracture patients. A previous cost-effectiveness analysis has been performed for the treatment of rotator cuff 
arthropathy, but not for the currently controversial management of proximal humerus fractures [46]. In the 
model by Coe et al, RTSA was the preferred treatment, as well, but using a much higher and less accepted 
WTP threshold.  A second prospective economic study on rotator cuff arthropathy reported a cost-utility for 
RTSA between $16,747/QALY and $26,920/QALY (US dollars, USD) at two years postoperatively [47]. 
Both studies [44, 45] also recognized the high sensitivity of their models to the utility lost due to 
complications from the operation and the cost of the implant. A third economic study [48] compared HA and 
RTSA on basis of data from the Nationwide Inpatient Sample database (2011) and found RTSA to be an 
independent risk factor for inpatient morbidity, mortality, and hospital costs [48]. 
 
The complication rates for elective shoulder arthroplasty differ noticeably from the values known for 
arthroplasty in the treatment of proximal humerus fractures [18-21].  In addition, patients who have sustained 
a proximal humerus fracture are clearly more likely to have an impaired baseline neuromuscular coordination 
when compared to non-fracture patients selected for elective shoulder arthroplasty [49]. Hence, the present 
study provides important guidance on the economic value of arthroplasty options used to treat shoulder 
fracture patients. 
 
A major strength of this study is its use of multiple data sources and meta-analysis data. In addition, many 
cost values were derived from the prospective multi-center Ontario Case Costing Initiative. Furthermore, the 
model’s conclusions were highly stable across one-way, two-way, and probabilistic sensitivity analyses.  
Despite the robust nature of the model’s results, the focus on the Canadian system limits the conclusions 
made to healthcare systems and populations with similar characteristics. For systems with larger healthcare 
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costs (such as the United States), the ICER is less likely to be cost-effective because the incremental costs 
between implants is typically larger; however, readers can use our model to determine how close the base 
case estimates are to their own healthcare system.  
 
Other model characteristics must also be considered.  This analysis was conducted from a single-payer 
perspective and did not account for indirect costs such as absence from work and need for nursing care. As 
this fracture most commonly affects elderly patients and the subsequent shoulder dysfunction of the injury 
has a tremendous impact on their general care dependency, it is likely that the patient and their caregiver will 
also incur considerable indirect costs associated to this injury.  
 
In an ideal situation such an analysis would be based on very long-term studies comparing costs and 
outcomes of patients randomized to the two groups. However, such studies are simply not available at 
present, yet policy decisions still need to be made. Mathematical models are commonly used to assess and 
forecast the relative effectiveness and cost effectiveness of alternative treatment strategies using a synthesis 
of the best available evidence [50]. The results, including the uncertainty in the results, often guide policy 
decisions, assist physicians in comparing treatment strategies, and help clinicians design clinical studies. 
 
In any cost-effectiveness analysis, the determinant of what treatment is economically preferred is highly 
dependent on the societal WTP threshold adopted. This study used a WTP threshold of $50,000 CAD per 
incremental QALY gained, which is less than the commonly cited threshold of $50,000 USD [28]. Other 
authors have even suggested higher thresholds to be appropriate [51,52].  With an incremental cost of only 
$13,679 CAD per incremental QALY, RTSA proved to be clearly below all commonly accepted WTP 
thresholds, and was highly cost-effective when compared to HA. A treatment that provides an ICER of 
$13,679 CAD would be categorized as a “recommended” medical intervention by the National Health 
Service in the UK [53] and is far below the commonly cited U.S. Medicare willingness to threshold for renal 
dialysis [52,54]. 
 
In conclusion, when comparing HA and RTSA in the treatment of complex proximal humeral fractures in 
elderly patients from a single-payer governmental perspective, RTSA approaches the willingness-to pay 
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Figure 1 Decision tree representing the comparison of RTSA vs. HA for the treatment of complex proximal 




Figure 2 Markov model representing transitional health states. The Markov modeling process commences 2-
years after the initial surgical treatment. 
 
Note:  HA, hemiarthroplasty; RTSA, reverse total shoulder arthroplasty; PF, periprosthetic fracture; AL, 
aseptic loosening; LI, late infection. 
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Figure 3 Results of two-way sensitivity analysis. The RTSA implant costs and the probability of an early 




Figure 4 Results of Monte Carlo probabilistic sensitivity analysis. The incremental cost-effectiveness ratio 
for RTSA compared to HA is shown. A willingness to pay threshold of $50,000 per incremental QALY 




Figure 5 Acceptability curve of RTSA versus HA for the treatment of proximal humerus fractures in the 
elderly. This figure shows the fraction of the time RTSA or HA was cost-effective at various willingness-to-





Table 1 Model parameters and ranges used in the probabilistic sensitivity analysis 
Model parameters Base Case 
Value 
Range Distribution Source 
Risk of complications  (probability)     
Hemiarthroplasty     
 Early complication 0.100 0.063 – 0.146 Beta 12,18-21 
 If early complication, requires reoperation 0.500 0.251 – 0.701 Beta 12,18-21 
 Annual risk of late infection 0.002 0.001 – 0.003 Beta 12,18,19,37 
 Annual risk of late late aseptic loosening 0.005 0.004 – 0.006 Beta 12,18,19,37 
 Annual risk of late late periprosthetic fracture 0.001 0.001 – 0.002 Beta 12,18,19,37 
      
Reverse Total Shoulder Arthroplasty     
 Early complication 0.150 0.091 – 0.220 Beta 18-21 
 If early complication, requires reoperation 0.400 0.230 – 0.570  Beta 12,18-21 
 Annual risk of late infection 0.002 0.001 – 0.003 Beta 12,18,19,37 
 Annual risk of late late aseptic loosening 0.005 0.004 – 0.006 Beta 12,18,19,37 
 Annual risk of late late periprosthetic fracture 0.001 0.001 – 0.002 Beta 12,18,19,37 
      
Possible health states (utilities)     
 Excellent Function 0.817  0.588 – 1.000 Gamma 12,31,40 
 Good Function 0.701  0.588 – 0.824 Gamma 12,31,40 
 Poor Function / No Pain 0.451  0.224 – 0.764 Gamma 12,31,40 
 Poor Function / Pain 0.217  0.126 – 0.344 Gamma 12,31,40 
 Very Poor Function/ Pain 0.154  0.007 – 0.300 Gamma 12,31,40 
      
Cost estimates ($CDN)     
Hemiarthroplasty     
 Initial procedure $15,539  7,613 – 54,332 Gamma 42,43 
 Follow-up visit $94  38 - 172 Gamma 42,43 
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 Short-term complications   Gamma 42,43 
 Major revision  $21,446 4,642 – 48,161 Gamma 42,43 
 Minor revision  $12,852 9,863 – 56,582 Gamma 42,43 
 Mid- and Long-term complications   Gamma 42,43 
 Late infection  $20,196 6,900 – 41,883 Gamma 42,43 
 Aseptic loosening $19196 6,711 – 42,912 Gamma 42,43 
 Periprosthetic fracture $14,556 5,274 – 30,750 Gamma 42,43 
      
Reverse Total Shoulder Arthroplasty     
 Initial procedure $21,059 10,892 – 36,282 Gamma 42,43 
 Follow-up visit $94 38 - 172 Gamma 42,43 
 Short-term complications   Gamma 42,43 
 Major revision  $21,307 12,345 – 35,324 Gamma 42,43 
 Minor revision  $12,852 4,406 – 27,437 Gamma 42,43 
 Mid- and Long-term complications   Gamma 42,43 
 Late infection $22,307 14,436 – 31,499 Gamma 42,43 
 Aseptic loosening $21,307 14,437 – 31,499 Gamma 42,43 








Table 2 Probability of each possible each health state two-years after surgical treatment 
 
Short term outcomes  Probability 
Hemiarthroplasty  
 Excellent Function (Elevation >120°) 0.336  
 Good Function (Elevation 90° to 120°) 0.353  
 Poor Function / No Pain (Elevation <90°) 0.055  
 Poor Function / Pain (Elevation <90°, Pain >5/10) 0.222  
 Death 0.034  
   
Reverse Total Shoulder Arthroplasty  
 Excellent Function (Elevation >120°) 0.411  
 Good Function (Elevation 90° to 120°) 0.351  
 Poor Function / No Pain (Elevation <90°) 0.051  
 Poor Function / Pain (Elevation <90°, Pain >5/10) 0.153  











ICER (Cost Per  
Incremental QALY Gained) 
 HA $18,348 5.76  
 RTSA $24,219 6.19 $13,679 
 
 
 
 
 
 
 
 
